[HTML][HTML] Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study

R Nanda, LQM Chow, EC Dees, R Berger… - Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
R Nanda, LQM Chow, EC Dees, R Berger, S Gupta, R Geva, L Pusztai, K Pathiraja, G Aktan…
Journal of Clinical oncology, 2016ncbi.nlm.nih.gov
Purpose Immune checkpoint inhibition has been demonstrated to be an effective anticancer
strategy. Several lines of evidence support the study of immunotherapy in triple-negative
breast cancer (TNBC). We assessed the safety and antitumor activity of the programmed cell
death protein 1 (PD-1) inhibitor pembrolizumab in patients with advanced TNBC. Methods
Abstract
Purpose
Immune checkpoint inhibition has been demonstrated to be an effective anticancer strategy. Several lines of evidence support the study of immunotherapy in triple-negative breast cancer (TNBC). We assessed the safety and antitumor activity of the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab in patients with advanced TNBC.
Methods
ncbi.nlm.nih.gov